Bremelanotide (PT-141) Protocol Guide
Bremelanotide (PT-141, brand name Vyleesi) is an FDA-approved melanocortin receptor agonist that activates MC3R and MC4R receptors in the central nervous system to enhance sexual desire and arousal. Unlike PDE5 inhibitors (sildenafil, tadalafil) which act peripherally on blood flow, bremelanotide works centrally in the brain by modulating dopaminergic and oxytocinergic pathways involved in sexual motivation. Approved for hypoactive sexual desire disorder (HSDD) in premenopausal women at 1.75mg subcutaneously as-needed, it has also been researched in men with erectile dysfunction refractory to PDE5 inhibitors. This protocol covers as-needed and research dosing, timing optimization, blood pressure monitoring, and nausea management strategies.
Protocol Overview
- Compound
- Bremelanotide (PT-141 / Vyleesi)
- Category
- Sexual Function / Melanocortin Agonist
- Mechanism
- MC3R/MC4R agonist; centrally acting to enhance sexual desire via dopaminergic and oxytocinergic modulation
- Molecular Weight
- 1,025.2 g/mol
- Half-Life
- ~2.7 hours
- Form
- Auto-injector (1.75mg) or lyophilized powder
- Route
- Subcutaneous
- Frequency
- As needed (max 1x per 24h, max 8x per month)
- FDA Status
- Approved (2019) for HSDD in premenopausal women
Dosing Protocol
| Protocol | Dose | Frequency | Route | Notes |
|---|---|---|---|---|
| FDA-Approved (Women) | 1.75 mg | As needed | SubQ | 45+ min before activity |
| Low-Dose Research | 0.5 mg | As needed | SubQ | Reduced nausea risk |
| Standard Research | 1.0 mg | As needed | SubQ | Common research dose |
| Male Research | 1.0-2.0 mg | As needed | SubQ | Phase 2 trial range |
Key principle: Administer at least 45 minutes before anticipated sexual activity. Effects onset at 45-60 minutes and last 6-12 hours. Do not exceed 1 dose per 24 hours or 8 doses per month per FDA labeling. Lower doses (0.5-1.0mg) may reduce nausea while retaining efficacy.
Administration Guide
Subcutaneous Injection
- Device: Auto-injector (Vyleesi) or insulin syringe from reconstituted vial
- Site: Abdomen or anterior thigh
- Timing: 45+ minutes before anticipated activity
- Anti-nausea tip: Eat a light meal 1-2 hours before injection
- Onset: 45-60 minutes; peak ~1.5 hours
Storage & Reconstitution
- Auto-injector: Room temperature, protect from light
- Lyophilized vial: Reconstitute with BAC water
- Refrigerate: After reconstitution, use within 28 days
- Vial math: 10mg vial + 2mL BAC water = 5mg/mL; 1.75mg = 35 units
Expected Timeline
Side Effects & Monitoring
Common Side Effects
- Nausea (40% - most common, usually transient)
- Flushing / facial warmth (20%)
- Injection site reactions (13%)
- Headache (11%)
- Transient blood pressure increase
- Skin hyperpigmentation (with repeated use)
Nausea can be mitigated by eating a light meal before dosing and starting at a lower dose (0.5-1mg).
Precautions
- Contraindicated with uncontrolled hypertension
- Causes transient BP increase (~6/3 mmHg average)
- Not for use with cardiovascular disease
- May cause skin darkening with chronic use (melanocyte activation)
- Do not use more than 8x per month
- Not recommended during pregnancy
Stacking Recommendations
Compatible Compounds
- Oxytocin: Complementary bonding and arousal (intranasal)
- Kisspeptin: Reproductive hormone axis support
- BPC-157: General neuroprotection and gut support
- Zinc / Magnesium: Mineral support for hormonal function
Avoid Combining With
- Melanotan II: Overlapping MC receptor activation; additive side effects
- Antihypertensives: May mask BP increase signal
- Naltrexone: May reduce melanocortin effects
Blood Work Recommendations
| Panel | Markers | Timing |
|---|---|---|
| Cardiovascular | Blood pressure, heart rate | Before and 1 hour after first use |
| Hormonal Panel | Testosterone, estradiol, LH, FSH | Baseline (if using regularly) |
| Melanocyte Assessment | Dermatological skin check | Every 6 months with regular use |
| Metabolic | CMP, liver function | Baseline (if using regularly) |
Blood pressure monitoring before and after first use is the most important safety measure. Skin checks for hyperpigmentation changes are recommended with repeated use due to melanocyte activation.
Related Tools & Resources
